Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $340M | $321M | $431M | $512M | $512M | $573M | $568M |
| Revenue growth | — | -5.6% | 34.2% | 18.8% | 0.0% | 11.9% | -0.9% |
| Gross profit | $249M | $234M | $303M | $331M | $328M | $388M | $388M |
| Gross margin | 73.3% | 72.7% | 70.3% | 64.6% | 64.1% | 67.7% | 68.3% |
| Operating income | $31.2M | $21.2M | $12.1M | -$167M | -$81.7M | -$15.2M | $54.0M |
| Operating margin | 9.2% | 6.6% | 2.8% | -32.7% | -16.0% | -2.7% | 9.5% |
| Net income | $6.85M | $16.4M | $19.4M | -$159M | -$156M | -$36.1M | $22.7M |
| Net margin | 2.0% | 5.1% | 4.5% | -31.0% | -30.5% | -6.3% | 4.0% |
| EPS (diluted) | — | — | -$0.15 | -$2.59 | -$2.49 | -$0.56 | $0.33 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $40.7M | $71.8M | $23.0M | -$13.5M | $15.3M | $38.8M | $74.7M |
| Capital expenditures | $2.34M | $16.6M | $13.5M | $1.48M | $7.36M | $1.01M | $2.56M |
| Free cash flow | $38.4M | $55.2M | $9.47M | -$15.0M | $7.98M | $37.8M | $72.1M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $64.5M | $86.8M | $43.9M | $30.2M | $37.0M | $41.6M | $51.2M |
| Total assets | — | $494M | $1.23B | $1.37B | $811M | $728M | $684M |
| Total liabilities | — | $350M | $618M | $960M | $590M | $542M | $455M |
| Long-term debt | — | $173M | $340M | $385M | $367M | $308M | $279M |
| Shareholders' equity | — | — | $459M | $325M | $174M | $148M | $184M |
| Retained earnings | — | — | -$6.60M | -$165M | -$322M | -$358M | -$335M |
| Shares (wtd avg diluted) | — | — | 45.5M | 61.4M | 62.6M | 64.5M | 68.9M |
Every figure is extracted from Bioventus Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.